Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021239 | 1.00 | CYP3A4 (0.36) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL4951192 | 0.96 | CYP3A4 (0.38) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL13250784 | 0.93 | KEAP1 (0.36) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL7277568 | 0.89 | CYP24A1 (0.40) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL3290837 | 0.89 | CYP24A1 (0.40) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL13670636 | 0.88 | CYP24A1 (0.39) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL20601810 | 0.82 | CYP3A4 (0.37) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL23611465 | 0.81 | CA12 (0.42) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL25390430 | 0.81 | CA12 (0.42) | CYP3A4CA12CA1CA9CYP2C19 | |
| SCHEMBL17185826 | 0.81 | CA12 (0.42) | CYP3A4CA12CA1CA9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344125-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| US-20050164235-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue; drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs for hepatitis virus | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179309-A1 | MODIFIED iRNA AGENTS | HNRNPA0, HNRNPA1, SNRPA | CYP3A4 4535/4885CA12 1723/4885CA1 3108/4885 |
| US-20050164235-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue; drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs for hepatitis virus | HAVCR2, LDLR, RNASE1 | CYP3A4 2459/4885CA12 3391/4885CA1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.